## Ruta Petraitiene

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9776321/publications.pdf

Version: 2024-02-01

20 papers 1,260 citations

567281 15 h-index 19 g-index

20 all docs

20 docs citations

20 times ranked

978 citing authors

#	Article	IF	CITATIONS
1	Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in Experimental $\langle i \rangle$ Candida albicans $\langle i \rangle$ Infection of the Central Nervous System. Journal of Infectious Diseases, 2000, 182, 274-282.	4.0	342
2	Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia. Antimicrobial Agents and Chemotherapy, 2002, 46, 12-23.	3.2	179
3	The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental Hematogenous <i>Candida</i> Meningoencephalitis: Implications for Echinocandin Therapy in Neonates. Journal of Infectious Diseases, 2008, 197, 163-171.	4.0	168
4	Antifungal Activity of LY303366, a Novel Echinocandin B, in Experimental Disseminated Candidiasis in Rabbits. Antimicrobial Agents and Chemotherapy, 1999, 43, 2148-2155.	3.2	103
5	(1→3)-β-d-Glucan in Cerebrospinal Fluid as a Biomarker for <i>Candida</i> and <i>Aspergillus</i> li>Infections of the Central Nervous System in Pediatric Patients. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 277-286.	1.3	61
6	Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in Rabbits. Antimicrobial Agents and Chemotherapy, 2001, 45, 596-600.	3.2	60
7	Cerebrospinal Fluid and Plasma (1â†'3)-β- <scp>d</scp> -Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous <i>Candida</i> Meningoencephalitis. Antimicrobial Agents and Chemotherapy, 2008, 52, 4121-4129.	3.2	54
8	Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrobial Agents and Chemotherapy, 2004, 48, 1188-1196.	3.2	44
9	Galactomannan Antigenemia after Infusion of Gluconate-Containing Plasma-Lyte. Journal of Clinical Microbiology, 2011, 49, 4330-4332.	3.9	41
10	Efficacy, Plasma Pharmacokinetics, and Safety of Icofungipen, an Inhibitor of Candida Isoleucyl-tRNA Synthetase, in Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits. Antimicrobial Agents and Chemotherapy, 2005, 49, 2084-2092.	3.2	34
11	Safety and Efficacy of Multilamellar Liposomal Nystatin against Disseminated Candidiasis in Persistently Neutropenic Rabbits. Antimicrobial Agents and Chemotherapy, 1999, 43, 2463-2467.	3.2	32
12	Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. Clinical Pharmacokinetics, 2018, 57, 1483-1491.	3.5	32
13	Successful treatment of <i> Aspergillus &lt; /i &gt; ventriculitis through voriconazole adaptive pharmacotherapy, immunomodulation, and therapeutic monitoring of cerebrospinal fluid <math>(1\hat{a}^{\dagger})^2</math>-D-glucan. Medical Mycology, 2017, 55, 109-117.</i>	0.7	29
14	Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2015, 59, 2735-2745.	3.2	26
15	Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	21
16	OUP accepted manuscript. Medical Mycology, 2017, 55, 859-868.	0.7	19
17	Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous <i>Candida</i> Meningoencephalitis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	6
18	Posaconazole Alone and in Combination with Caspofungin for Treatment of Experimental Exserohilum rostratum Meningoencephalitis: Developing New Strategies for Treatment of Phaeohyphomycosis of the Central Nervous System. Journal of Fungi (Basel, Switzerland), 2020, 6, 33.	3.5	6

#	Article	IF	CITATIONS
19	Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters. Antimicrobial Agents and Chemotherapy, 2021, 65, e0116821.	3.2	3
20	1388Eradication of Medically Important Multidrug Resistant Bacteria and Fungi Using PurpleSun Inc. Multivector UV Technology. Open Forum Infectious Diseases, 2014, 1, S365-S365.	0.9	0